211 related articles for article (PubMed ID: 28349991)
1. Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action.
Irace C; Misso G; Capuozzo A; Piccolo M; Riccardi C; Luchini A; Caraglia M; Paduano L; Montesarchio D; Santamaria R
Sci Rep; 2017 Mar; 7():45236. PubMed ID: 28349991
[TBL] [Abstract][Full Text] [Related]
2. Exploring cellular uptake, accumulation and mechanism of action of a cationic Ru-based nanosystem in human preclinical models of breast cancer.
Piccolo M; Misso G; Ferraro MG; Riccardi C; Capuozzo A; Zarone MR; Maione F; Trifuoggi M; Stiuso P; D'Errico G; Caraglia M; Paduano L; Montesarchio D; Irace C; Santamaria R
Sci Rep; 2019 May; 9(1):7006. PubMed ID: 31065032
[TBL] [Abstract][Full Text] [Related]
3. Conjugation of a Ru(II) arene complex to neomycin or to guanidinoneomycin leads to compounds with differential cytotoxicities and accumulation between cancer and normal cells.
Grau-Campistany A; Massaguer A; Carrion-Salip D; Barragán F; Artigas G; López-Senín P; Moreno V; Marchán V
Mol Pharm; 2013 May; 10(5):1964-76. PubMed ID: 23510087
[TBL] [Abstract][Full Text] [Related]
4. Novel ruthenium complexes ligated with 4-anilinoquinazoline derivatives: synthesis, characterisation and preliminary evaluation of biological activity.
Ji L; Zheng W; Lin Y; Wang X; Lü S; Hao X; Luo Q; Li X; Yang L; Wang F
Eur J Med Chem; 2014 Apr; 77():110-20. PubMed ID: 24631730
[TBL] [Abstract][Full Text] [Related]
5. Improving Cytotoxicity against Breast Cancer Cells by Using Mixed-Ligand Ruthenium(II) Complexes of 2,2'-Bipyridine, Amino Acid, and Nitric Oxide Derivatives as Potential Anticancer Agents.
Gaspari APS; da Silva RS; Carneiro ZA; de Carvalho MR; Carvalho I; Pernomian L; Ferreira LP; Ramos LCB; de Souza GA; Formiga ALB
Anticancer Agents Med Chem; 2021; 21(12):1602-1611. PubMed ID: 33081686
[TBL] [Abstract][Full Text] [Related]
6. Cellular responses of BRCA1-defective HCC1937 breast cancer cells induced by the antimetastasis ruthenium(II) arene compound RAPTA-T.
Nhukeaw T; Hongthong K; Dyson PJ; Ratanaphan A
Apoptosis; 2019 Aug; 24(7-8):612-622. PubMed ID: 31016421
[TBL] [Abstract][Full Text] [Related]
7. Insights into anticancer activity and mechanism of action of a ruthenium(II) complex in human esophageal squamous carcinoma EC109 cells.
Guo L; Lv G; Qiu L; Yang H; Zhang L; Yu H; Zou M; Lin J
Eur J Pharmacol; 2016 Sep; 786():60-71. PubMed ID: 27262377
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, characterization, and anticancer activity of ruthenium(II)-β-carboline complex.
Chen Y; Qin MY; Wu JH; Wang L; Chao H; Ji LN; Xu AL
Eur J Med Chem; 2013; 70():120-9. PubMed ID: 24141202
[TBL] [Abstract][Full Text] [Related]
9. Dimetallic Ru(II) arene complexes appended on bis-salicylaldimine induce cancer cell death and suppress invasion via p53-dependent signaling.
Rahman FU; Bhatti MZ; Ali A; Duong HQ; Zhang Y; Ji X; Lin Y; Wang H; Li ZT; Zhang DW
Eur J Med Chem; 2018 Sep; 157():1480-1490. PubMed ID: 30282320
[TBL] [Abstract][Full Text] [Related]
10. Structural basis and anticancer properties of ruthenium-based drug complexed with human serum albumin.
Zhang Y; Ho A; Yue J; Kong L; Zhou Z; Wu X; Yang F; Liang H
Eur J Med Chem; 2014 Oct; 86():449-55. PubMed ID: 25200980
[TBL] [Abstract][Full Text] [Related]
11. Ruthenium complexes containing bis-benzimidazole derivatives as a new class of apoptosis inducers.
Li L; Wong YS; Chen T; Fan C; Zheng W
Dalton Trans; 2012 Jan; 41(4):1138-41. PubMed ID: 22159211
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol-based nucleolipid-ruthenium complex stabilized by lipid aggregates for antineoplastic therapy.
Simeone L; Mangiapia G; Vitiello G; Irace C; Colonna A; Ortona O; Montesarchio D; Paduano L
Bioconjug Chem; 2012 Apr; 23(4):758-70. PubMed ID: 22369596
[TBL] [Abstract][Full Text] [Related]
13. Differential Cytotoxicity, Cellular Uptake, Apoptosis and Inhibition of BRCA1 Expression of BRCA1-Defective and Sporadic Breast Cancer Cells Induced by an Anticancer Ruthenium(II)-Arene Compound, RAPTA-EA1.
Ratanaphan A; Nhukeaw T; Hongthong K; Dyson PJ
Anticancer Agents Med Chem; 2017; 17(2):212-220. PubMed ID: 27039925
[TBL] [Abstract][Full Text] [Related]
14.
Gopalakrishnan D; Saravanan S; Merckx R; Madan Kumar A; Khamrang T; Velusamy M; Vasanth K; Sunitha S; Hoogenboom R; Maji S; Ganeshpandian M
Dalton Trans; 2021 Jun; 50(23):8232-8242. PubMed ID: 34037018
[TBL] [Abstract][Full Text] [Related]
15. Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine.
Nhukeaw T; Temboot P; Hansongnern K; Ratanaphan A
BMC Cancer; 2014 Feb; 14():73. PubMed ID: 24507701
[TBL] [Abstract][Full Text] [Related]
16. Labile ruthenium(ii) complexes with extended phenyl-substituted terpyridyl ligands: synthesis, aquation and anticancer evaluation.
Huang H; Zhang P; Chen Y; Ji L; Chao H
Dalton Trans; 2015 Sep; 44(35):15602-10. PubMed ID: 26245234
[TBL] [Abstract][Full Text] [Related]
17. Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems.
Ferraro MG; Piccolo M; Misso G; Maione F; Montesarchio D; Caraglia M; Paduano L; Santamaria R; Irace C
Cells; 2020 Jun; 9(6):. PubMed ID: 32517101
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, interaction with DNA, cytotoxicity, cell cycle arrest and apoptotic inducing properties of ruthenium(II) molecular "light switch" complexes.
Shobha Devi C; Anil Kumar D; Singh SS; Gabra N; Deepika N; Kumar YP; Satyanarayana S
Eur J Med Chem; 2013 Jun; 64():410-21. PubMed ID: 23665797
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, characterization, antiproliferative and molecular docking study of new half sandwich Ir(III), Rh(III) and Ru(II) complexes.
Thangavel S; Paulpandi M; Friedrich HB; Murugan K; Kalva S; Skelton AA
J Inorg Biochem; 2016 Jun; 159():50-61. PubMed ID: 26918899
[TBL] [Abstract][Full Text] [Related]
20. Anticancer activity of structurally related ruthenium(II) cyclopentadienyl complexes.
Côrte-Real L; Mendes F; Coimbra J; Morais TS; Tomaz AI; Valente A; Garcia MH; Santos I; Bicho M; Marques F
J Biol Inorg Chem; 2014 Aug; 19(6):853-67. PubMed ID: 24562604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
